Skip to main content
SpringerLink
Log in

Mifamurtide

CGP 19835, CGP 19835A, L-MTP-PE, Liposomal MTP-PE, MLV 19835A, MTP-PE, Muramyltripeptide Phosphatidylethanolamine

  • Adis R&D Profile
  • Published:
Drugs in R & D Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II

References

  1. Immuno-Designed Molecules. IDM Acquires Assets from the American Company Jenner. Media Release: 9 Apr 2003. Available from URL: http://www.idm-biotech.com

    Google Scholar 

  2. IDM Pharma Inc. IDM and GENESIS Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in South East Europe. Media Release: 21 Feb 2006. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  3. IDM Pharma Inc. IDM and Medison Pharma Sign an Exclusive Marketing Agreement for Junovan(TM) in Israel. Media Release: 14 Mar 2006. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  4. IDM (Immuno-Designed Molecules). IDM and Cambridge Laboratories Sign an Exclusive Marketing Agreement for Junovan(TM) (Mepact) in the United Kingdom and Ireland. Media Release: 21 Jun 2005. Available from URL: http://www.idm-biotech.com

    Google Scholar 

  5. IDM Pharma Inc. IDM Pharma to Raise $25 Million in Registered Direct Offering. Media Release: 21 Jun 2007. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  6. IDM Pharma Inc. IDM Pharma Receives Not Approvable Letter for Mifamurtide (L-MTP-PE) for the Treatment of Osteosarcoma. Media Release: 27 Aug 2007. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  7. IDM Pharma. IDM Pharma Submits New Drug Application to the FDA for Junovan™ (mifamurtide) in the Treatment of Osteosarcoma. Media Release: 27 Oct 2006. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  8. IDM Pharma. IDM Pharma Submits Filing for European Market Approval of Mepact™ (mifamurtide, Junovan™ in the US) in the Treatment of Osteosarcoma. Media Release: 8 Nov 2006. Available from URL: http://www.businesswire.com

    Google Scholar 

  9. IDM Pharma Inc. IDM Pharma Announces Data Presentation From Mifamurtide (L-MTP-PE) Compassionate Use Program. Media Release: 2 Nov 2007. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  10. IDM. Mepact, IDM’ss Most Advanced Product, Receives ‘Orphan Medicinal Product’ Designation for the Treatment of Osteosarcoma in the European Union. Media Release: 8 Jul 2004. Available from URL: http://www.idm-biotech.com

    Google Scholar 

  11. Verweij J, Judson I, Steward W, et al. Phase II study of liposomal muramyl tripeptide phosphatidylethanolamine (MTP/ PE) in advanced soft tissue sarcomas of the adult. An EORTC Soft Tissue and Bone Sarcoma Group Study. European Journal of Cancer: Part A 30A: 842–843, No. 6, 1994

    Article  PubMed  CAS  Google Scholar 

  12. Kahn J, Chernoff D, Sinangil F. Phase 1 dose escalation MTP-PE study of an HIV-1 GP120 vaccine in sero-negative adults. AIDS Research and Human Retroviruses 9 (Suppl. 1): 112, Oct 1993

    Google Scholar 

  13. IDM. IDM Pharma Announces Acceptance for Review of the NDA for Junovan™ (Mifamurtide). Media Release: 27 Dec 2006. Available from URL: http://www.idm-pharma.com

    Google Scholar 

  14. Dinney CPN, Utsugi T, Fidler IJ, et al. Immunotherapy of murine renal adenocarcinoma by systemic administration of liposomes containing the synthetic macrophage activator CGP 31362 or CGP 19835A in combination with interleukin 2 or gamma-interferon. Cancer Research 52: 1155–1161, 1 Mar 1992

    PubMed  CAS  Google Scholar 

  15. Asao T, Shibata HR, Batist G, et al. Eradication of hepatic metastases of carcinoma H-59 by combination chemoimmu-notherapy with liposomal muramyl tripeptide, 5-fluorouracil, and leucovorin. Cancer Research 52: 6254–6257, 15 Nov 1992

    PubMed  CAS  Google Scholar 

  16. Bezault J, Walsh C, Tarcsay L, et al. Analysis of the antimetastatic effects of synthetic muramyl tripeptide (CGP 19835A) encapsulated in liposomes in combination with other immuno-modulatory agents and chemotherapeutic drugs. In Vivo 7: 487–491, Nov–Dec 1993

    Google Scholar 

  17. Kleinerman ES, Snyder JS, Jaffe N. Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. Journal of Clinical Oncology 9: 259–267, Feb 1991

    PubMed  CAS  Google Scholar 

  18. Lazdins JK, Woods-Cook K, Walker M. The lipophilic muramyl peptide MTP-PE is a potent inhibitor of HIV replication in macrophages. AIDS Research and Human Retroviruses 6: 1157–1161, Oct 1990

    Article  PubMed  CAS  Google Scholar 

  19. Fujimaki W, Itoh K, An T. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP-19835A lipid). Cancer Biotherapy 8: 307–318, No. 4, 1993

    Article  PubMed  CAS  Google Scholar 

  20. Gianan MAV, Kleinerman ES. Liposomal muramyl tripeptide (CGP 19835A lipid) therapy for resectable melanoma in patients who were at high risk for relapse: an update. Cancer Biotherapy and Radiopharmaceuticals 13: 363–368, No. 5, 1998

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mifamurtide. Drugs R&D 9, 131–135 (2008). https://doi.org/10.2165/00126839-200809020-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200809020-00007

Keywords

Search

Navigation